In this study, we conducted a CRISPR-dCas9 interference screen in a BRCA1/2-proficient breast cancer cell line to identify genes that modulate the cell response to the PARP inhibitor olaparib and identified IRF9 as a candidate. Here, IRF9 is linked to breast carcinoma.